secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2026-06-15T11:09:44+00:00
Accession:  0001193125-26-270280
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes announces orphan drug designations for alixorexton in US for IH and EU for narcolepsy
--------------------------------------------------------------------------------

- FDA grants orphan drug designation to alixorexton for idiopathic hypersomnia.
- European Commission grants orphan drug designation to alixorexton for narcolepsy.
- Alixorexton is an oral OX2R agonist in phase 3 for narcolepsy and phase 2 for IH.
- ODD provides market exclusivity (7 yrs US, 10 yrs EU) if approved.
- Alixorexton previously received FDA Breakthrough Therapy for NT1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000119312526270280/0001193125-26-270280-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000119312526270280/alks-20260615.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-270280

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer